Revelation Biosciences Reaches Agreement with FDA on Gemini Approval Pathway for AKI

We are grateful for the collaborative feedback from FDA on the Gemini program, which provides us a clear and expedient path forward for seeking approval of Gemini as a treatment for AKI,” said, James ...

Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026)

Title: Gemini restores normal innate immune response in CKD patients Presenter: Robin Marsden, Senior Vice President of Biology, Revelation Biosciences Date/Time: Sunday, March 29, 2026 5:30 p.m.
Rutland Herald

Revelation Biosciences Announces Initiation of GMP Manufacturing of GEMINI and Placebo to Support Later Stage Clinical Development

SAN DIEGO, CA / ACCESS Newswire / January 7, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation" ...